What after Robert Terifay’s Insider Sale of Regeneron Pharmaceuticals (REGN) Stock?; Last Week Malibu Boats (MBUU) Analysts

June 19, 2017 - By wolcottdaily

Among 4 analysts covering Malibu Boats (NASDAQ:MBUU), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Malibu Boats had 4 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Market Perform” rating on Tuesday, May 10 by BMO Capital Markets. The stock of Malibu Boats Inc (NASDAQ:MBUU) earned “Hold” rating by Zacks on Tuesday, September 22. The stock of Malibu Boats Inc (NASDAQ:MBUU) earned “Buy” rating by B. Riley & Co on Thursday, February 25. As per Tuesday, August 11, the company rating was initiated by KeyBanc Capital Markets. See Malibu Boats Inc (NASDAQ:MBUU) latest ratings:

Robert Terifay, the EVP Commercial of Regeneron Pharmaceuticals Inc made a sudden trade for 21,147 shares with an average price per share of $468.2 in the public firm, that are amounting to $9,900,814 US Dollars. And, It’s sure Robert’s trade isn’t going to stay disregarded as he now is holding 24,992 shares – ( 0.02% of Regeneron Pharmaceuticals Inc’s Market Cap ).

Investors sentiment decreased to 1.41 in 2016 Q4. Its down 0.56, from 1.97 in 2016Q3. It is negative, as 11 investors sold Malibu Boats Inc shares while 30 reduced holdings. 19 funds opened positions while 39 raised stakes. 16.73 million shares or 3.12% more from 16.23 million shares in 2016Q3 were reported. Punch Mgmt Incorporated owns 560,364 shares or 1.06% of their US portfolio. Oxford Asset Mgmt reported 0.18% stake. Tower Cap Lc (Trc) holds 128 shares. Credit Suisse Ag holds 0% or 19,130 shares. Plante Moran Fin Advsr Ltd Limited Liability Company invested in 188 shares or 0% of the stock. Vanguard Gp invested in 0% or 661,276 shares. The United Kingdom-based Gsa Capital Llp has invested 0.1% in Malibu Boats Inc (NASDAQ:MBUU). Moreover, Manufacturers Life Ins The has 0% invested in Malibu Boats Inc (NASDAQ:MBUU) for 161,907 shares. Renaissance Techs Ltd reported 0.01% of its portfolio in Malibu Boats Inc (NASDAQ:MBUU). Blackrock owns 2,163 shares or 0% of their US portfolio. Macquarie Group reported 1.13 million shares. The Us-based Grandeur Peak Global Advsr Ltd Company has invested 0.78% in Malibu Boats Inc (NASDAQ:MBUU). California State Teachers Retirement Systems holds 0% or 37,212 shares in its portfolio. Penn Capital has 365,364 shares. Mckinley Mngmt Limited Liability Corporation Delaware has invested 0.14% in Malibu Boats Inc (NASDAQ:MBUU).

Since February 3, 2017, it had 0 insider purchases, and 2 insider sales for $1.41 million activity. Wilson Wayne R. also sold $704,689 worth of Malibu Boats Inc (NASDAQ:MBUU) shares. Anderson Ritchie L. had sold 35,000 shares worth $704,689 on Friday, February 3.

The stock increased 0.36% or $0.09 during the last trading session, reaching $24.89. About 119,043 shares traded. Malibu Boats Inc (NASDAQ:MBUU) has risen 77.33% since June 19, 2016 and is uptrending. It has outperformed by 60.63% the S&P500.

Malibu Boats, Inc. is a designer, manufacturer and marketer of performance sport boats. The company has market cap of $445.22 million. The Company’s divisions include the U.S. and Australia. It has a 19.95 P/E ratio. Each segment is engaged in the manufacturing, distribution, marketing and sale of performance sport boats.

Investors sentiment increased to 1.25 in 2016 Q4. Its up 0.29, from 0.96 in 2016Q3. It is positive, as 48 investors sold Regeneron Pharmaceuticals Inc shares while 151 reduced holdings. 60 funds opened positions while 188 raised stakes. 70.27 million shares or 1.15% less from 71.09 million shares in 2016Q3 were reported. Salient Capital Ltd Liability Com holds 1,350 shares. Bbva Compass State Bank Inc owns 10,223 shares. Highbridge Mngmt Limited Liability Com invested in 0.01% or 882 shares. Wellington Mgmt Ltd Liability Partnership owns 0.52% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 5.69 million shares. Marshall Wace Limited Liability Partnership reported 0.06% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Gateway Investment Advisers Limited Liability Com has invested 0.02% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). 4,800 were reported by Louisiana State Employees Retirement Systems. Calvert Mngmt stated it has 0.06% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Pinebridge Invests Limited Partnership reported 611 shares. Acadian Asset Mgmt Limited Liability Co invested 0% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Raymond James Ser Advsr Inc accumulated 2,935 shares. Klingenstein Fields And Ltd reported 1,900 shares. 1,860 are held by Bluemountain Mngmt Limited. Concert Wealth Management accumulated 0.06% or 720 shares. Ipg Advisors Ltd, California-based fund reported 2,650 shares.

Since January 11, 2017, it had 2 insider buys, and 6 selling transactions for $88.54 million activity. 3,000 shares were sold by BROWN MICHAEL S, worth $1.35M on Friday, May 12. $32.27M worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was bought by Sanofi on Wednesday, January 11. GOLDSTEIN JOSEPH L had sold 1,000 shares worth $482,550. STAHL NEIL had sold 2,812 shares worth $1.35 million. The insider VAGELOS P ROY sold 9,295 shares worth $4.26 million.

Among 22 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 12 have Buy rating, 0 Sell and 10 Hold. Therefore 55% are positive. Regeneron Pharmaceuticals Inc. has $700 highest and $300 lowest target. $547.15’s average target is 16.00% above currents $471.67 stock price. Regeneron Pharmaceuticals Inc. had 49 analyst reports since July 28, 2015 according to SRatingsIntel. On Monday, January 25 the stock rating was downgraded by Chardan Capital Markets to “Sell”. The firm earned “Neutral” rating on Tuesday, February 16 by Chardan Capital Markets. The stock has “Market Perform” rating by Wells Fargo on Wednesday, April 20. The firm has “Outperform” rating given on Wednesday, August 5 by RBC Capital Markets. The firm has “Outperform” rating by RBC Capital Markets given on Monday, July 27. Bernstein initiated the stock with “Outperform” rating in Wednesday, June 29 report. The company was initiated on Tuesday, March 15 by Gabelli. RBC Capital Markets maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Thursday, November 5 with “Outperform” rating. Robert W. Baird downgraded the stock to “Neutral” rating in Friday, August 5 report. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Outperform” rating by Credit Suisse on Tuesday, December 20.

The stock increased 2.56% or $11.76 during the last trading session, reaching $471.67. About 803,603 shares traded. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 17.40% since June 20, 2016 and is uptrending. It has outperformed by 0.70% the S&P500.

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The company has market cap of $49.11 billion. The Firm commercializes medicines for eye diseases, high low-density lipoprotein cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. It has a 56.75 P/E ratio. The Company’s marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: